v3.25.2
Summary of Significant Accounting Policies - Additional Information (Details)
3 Months Ended 6 Months Ended
May 21, 2025
USD ($)
Installment
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Summary Of Significant Accounting Policies [Line Items]            
Settlement agreement $ 36,000,000          
Payment term 4 years          
Accrued legal settlement charges $ 8,000,000          
Number of installment terms | Installment 4          
Imputed interest expense $ 4,400,000          
Settlement obligation $ 31,600,000          
Cross-license term 10 years          
Operating lease impairment charge   $ 0 $ 0 $ 0 $ 0  
Equity method investments   67,628,000   67,628,000   $ 74,545,000
Loss from equity method investments   (3,375,000) 0 (6,917,000) 0  
Sales   $ 240,678,000 221,910,000 $ 475,100,000 413,584,000  
Insulin Pump            
Summary Of Significant Accounting Policies [Line Items]            
Warranty period offered       4 years    
Deferred revenue     $ 1,100,000   1,100,000  
Net revenue recognized (deferred) for Tandem Choice program            
Summary Of Significant Accounting Policies [Line Items]            
Sales         $ 200,000  
Slim cartridges and infusion sets            
Summary Of Significant Accounting Policies [Line Items]            
Warranty period offered       6 months    
Patents            
Summary Of Significant Accounting Policies [Line Items]            
Intangible assets, net $ 13,300,000          
Amortization period 7 years